US Patent 9765066 Selective HDAC1 and HDAC2 inhibitors
Patent 9765066 was granted and assigned to Regenacy Pharmaceuticals on September, 2017 by the United States Patent and Trademark Office.
All edits
Edits on 11 Dec, 2023
Megan Gustafson
Edits made to:
Infobox (+1/-1 properties)
Infobox
Current Assignee
Current Assignee
Edits on 6 Dec, 2023
Golden AI
Edits made to:
Article (+365 characters)
Article
Patent abstract
Provided herein are compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with HDAC activity, particularly diseases or disorders that involve activity of HDAC1 and/or HDAC2. Such diseases include cancer, sickle-cell anemia, beta-thalassemia, and HIV.
Edits on 30 Sep, 2023
Golden AI
Edits made to:
Infobox (+2 properties)
Infobox
Patent Inventor Names
John H. van Duzer0
Ralph Mazitschek0
Edits on 19 Jul, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 13 Jul, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 09765066 Selective HDAC1 and HDAC2 inhibitors US Patent 9765066 Selective HDAC1 and HDAC2 inhibitors
Infobox
Patent Number
09765066
Patent Number
9765066
Edits on 14 Jan, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 09765066 Selective HDAC1 and HDAC2 inhibitors
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
09765066
Date of patent
September 19, 2017
Patent application number
15214061
Date Filed
July 19, 2016
Patent primary examiner
Find more entities like US Patent 9765066 Selective HDAC1 and HDAC2 inhibitors
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
